HLB Pharmaceutical Co., Ltd. (KOSDAQ: 047920)
South Korea
· Delayed Price · Currency is KRW 27,000
+350 (1.31%)
Sep 11, 2024, 1:56 PM KST
HLB Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|
Period Ending | Dec '19 Dec 31, 2019 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
| Net Income | 472.65 | 472.65 | -7,060 | -5,447 |
| Depreciation & Amortization | 1,640 | 1,640 | 1,143 | 1,055 |
| Loss (Gain) From Sale of Assets | 2.08 | 2.08 | 31.53 | 0.62 |
| Asset Writedown & Restructuring Costs | 438.73 | 438.73 | - | 509.63 |
| Loss (Gain) From Sale of Investments | -120.89 | -120.89 | -164.96 | 137.71 |
| Stock-Based Compensation | 105.02 | 105.02 | 431.59 | 454.54 |
| Provision & Write-off of Bad Debts | 124.02 | 124.02 | 16.52 | -40.69 |
| Other Operating Activities | 943.5 | 943.5 | 2,269 | 2,425 |
| Change in Accounts Receivable | -1,990 | -1,990 | 1,253 | 2,198 |
| Change in Inventory | -266.03 | -266.03 | -397.13 | -2,194 |
| Change in Accounts Payable | -2,452 | -2,452 | 946.47 | -253.52 |
| Change in Other Net Operating Assets | 2,456 | 2,456 | -246.42 | 370.51 |
| Operating Cash Flow | 1,353 | 1,353 | -1,777 | -784.3 |
| Capital Expenditures | -1,397 | -1,397 | -1,095 | -2,236 |
| Sale of Property, Plant & Equipment | 4 | 4 | 24.01 | 3.4 |
| Divestitures | - | - | 937.48 | - |
| Sale (Purchase) of Intangibles | -540.15 | -540.15 | -280.15 | -192.6 |
| Investment in Securities | -5,058 | -5,058 | 617.85 | 3,559 |
| Other Investing Activities | 43.27 | 43.27 | 105 | 37.98 |
| Investing Cash Flow | -6,938 | -6,938 | 309.09 | 1,172 |
| Short-Term Debt Issued | 1,892 | 1,892 | - | 1,725 |
| Long-Term Debt Issued | 10,914 | 10,914 | - | 1,400 |
| Total Debt Issued | 12,806 | 12,806 | - | 3,125 |
| Short-Term Debt Repaid | -5,546 | -5,546 | -371.25 | -1,400 |
| Long-Term Debt Repaid | -1,961 | -1,961 | -480 | -580 |
| Total Debt Repaid | -7,507 | -7,507 | -851.25 | -1,980 |
| Net Debt Issued (Repaid) | 5,299 | 5,299 | -851.25 | 1,145 |
| Financing Cash Flow | 5,299 | 5,299 | -851.25 | 1,145 |
| Foreign Exchange Rate Adjustments | - | - | -0.35 | 3,833 |
| Net Cash Flow | -286.08 | -286.08 | -2,320 | 5,365 |
| Free Cash Flow | -43.8 | -43.8 | -2,872 | -3,020 |
| Free Cash Flow Margin | -0.12% | -0.12% | -13.98% | -19.41% |
| Free Cash Flow Per Share | -3.16 | -3.16 | -212.19 | -252.31 |
| Cash Interest Paid | 288.41 | 288.41 | 207.01 | 274.48 |
| Cash Income Tax Paid | 58.82 | 58.82 | 17.4 | 4.95 |
| Levered Free Cash Flow | 1,808 | 1,808 | -540.14 | - |
| Unlevered Free Cash Flow | 2,554 | 2,554 | -2.9 | - |
| Change in Net Working Capital | -1,951 | -1,951 | -3,871 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.